Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (7834)	2/6/2003 4:46:48 PM
From: keokalani'nui	Read Replies (2) \| Respond to of 52153

Not sure where to put this, many places of interest. Merck Drops Development of Anxiety Drug Thursday February 6, 3:51 pm ET NEW YORK (Reuters) - Merck & Co. Inc. (NYSE:MRK - News) said it will drop development of an experimental anti-anxiety drug. The drug, known as Gaba Alpha 2/Alpha 3, was in mid-stage clinical trials designed to test its safety and efficacy. The Whitehouse Station, New Jersey-based drug company did not immediately say why it was dropping the drug. It said it will continue to test other anxiety medications. Industry analysts had expected the drug to garner annual sales of about $100 million by 2006, if it were to be approved. Industry observers had hoped it would have fewer side effects than standard treatments.